Active: Active Degree: PhD, ABCN Academic Title: Professor Institute Title: Director Email:firstname.lastname@example.org Office Phone: 314-516-8403 Fax Phone: 314-516-8405
Dr. Paul’s research program is focused on mechanisms of brain dysfunction in health conditions that primarily impact brain structures located deep beneath the surface of the cerebral cortex.
Dr. Paul’s research team has developed specific expertise in human immune deficiency syndrome (HIV), subcortical stroke, and early life trauma as three conditions that impact the integrity of deep brain structures including the white matter, basal ganglia, and limbic structures. Neuropsychological methods and neuroimaging techniques are primary research methods applied by Dr. Paul’s team to define behavioral and anatomical signatures of brain dysfunction in these conditions. Dr. Paul has a special interest in the application of these methods in resource-limited environments and he has active research programs in South Africa, Africa, Thailand, Vietnam, and Cambodia. He is a member of the HIV Cure Consortium and he works closely with collaborators at University of California San Francisco, Brown, Yale, and Washington University.
MIMH, partnered with National Council on Alcoholism & Drug Abuse (NCADA), under the leadership of the Missouri Department of Mental Health, is implementing and evaluating a SAMHSA-funded 5-year, $5 million grant to reduce opioid overdose events in the Eastern Region of the state.
Neuroimaging and Neurobehavioral Basis of Risky Decision Making in Adolescents
This project will develop neuroimaging biomarkers to assess the effects of risky decision making in HIV- and HIV+ adolescents.
Traumatic stress is a powerful moderator of physical and mental health outcomes. The impact of traumatic stress is visible across the lifespan from perinatal to late life stages of development. The biological mechanisms that drive symptom onset and expression have been the focus of intense study. Advances in neuroimaging and psychophysiology methods and applications now define clinical phenotypes that map onto biological indices. Treatment approaches that target specific cognitive, behavioral, and biological processes linked to traumatic symptoms show promise yet additional work is needed to optimize outcomes for individuals exposed to traumatic events.
This study will provide valuable data to facilitate our understanding of the relationship between physical frailty and neurocognitive impairment in older HIV+ participants and may help future adjunctive therapies.